Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates

IR700, a silicon phthalocyanine (SiPc) photosensitizer, is an antibody-drug conjugate payload used clinically. It is, however, the sole SiPc payload to date, possibly due to the difficulty of its synthesis, resulting from its asymmetric phathalocyanine skeleton. Here we report a new axially-substituted SiPc payload with easier synthesis. Trastuzumab conjugated with the SiPc showed light- and antigen-dependent cytotoxicity in HER2-overexpressed cancer cell lines.

Download Full-text

Potential Use of Monoclonal Antibody–Drug Conjugates to Prevent Drug Resistance

Mechanisms of Drug Resistance in Neoplastic Cells ◽

10.1016/b978-0-12-763362-6.50030-3 ◽

1988 ◽

pp. 371-383 ◽

Cited By ~ 1

Author(s):

CARL-WILHELM VOGEL ◽

REINHARD BREDEHORST ◽

MOUNANANDHAM PANNEERSELVAM ◽

CAROLE J. SPANGLER

Keyword(s):

Monoclonal Antibody ◽

Drug Resistance ◽

Antibody Drug Conjugates ◽

Drug Conjugates ◽

Potential Use ◽

Antibody Drug

Download Full-text

Immunotherapy of Melanoma with Monoclonal Antibody-Drug Conjugates

Human Melanoma ◽

10.1007/978-3-642-74496-9_28 ◽

1990 ◽

pp. 399-412

Author(s):

R. A. Reisfeld

Keyword(s):

Monoclonal Antibody ◽

Antibody Drug Conjugates ◽

Drug Conjugates ◽

Antibody Drug

Download Full-text

Monoclonal Antibody Drug Conjugates for Cancer Therapy

Prodrugs - Biotechnology: Pharmaceutical Aspects ◽

10.1007/978-0-387-49785-3_14 ◽

2007 ◽

pp. 507-524 ◽

Cited By ~ 1

Author(s):

Peter D. Senter ◽

Damon L. Meyer

Keyword(s):

Monoclonal Antibody ◽

Cancer Therapy ◽

Antibody Drug Conjugates ◽

Drug Conjugates ◽

Antibody Drug

Download Full-text

Trastuzamab antibody drug conjugates demonstrate robustin vitroantitumor activity in HER2 amplified breast cancer cell lines

10.1158/diag-10-b19 ◽

2010 ◽

Author(s):

Sankar Mohan ◽

Carol O'Brien ◽

Heidi Savage ◽

Gail Phillips ◽

Howard Stern ◽

...

Keyword(s):

Breast Cancer ◽

Cell Lines ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Cancer Cell Lines ◽

Breast Cancer Cell Lines ◽

Antibody Drug Conjugates ◽

Drug Conjugates ◽

Antibody Drug

Download Full-text

Antibody–Drug Conjugates for Cancer Therapy

Molecules ◽

10.3390/molecules25204764 ◽

2020 ◽

Vol 25 (20) ◽

pp. 4764

Author(s):

Umbreen Hafeez ◽

Sagun Parakh ◽

Hui K. Gan ◽

Andrew M. Scott

Keyword(s):

Monoclonal Antibody ◽

Molecular Imaging ◽

Cancer Therapy ◽

Normal Tissue ◽

Clinical Development ◽

Antibody Drug Conjugates ◽

Drug Conjugates ◽

Novel Drugs ◽

Antibody Drug

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.

Download Full-text